Breaking News

Cardurion Raises $260M Series B Financing

Proceeds will be used to support later-stage clinical trials with the company’s two lead drug candidates.

Author Image

By: Charlie Sternberg

Associate Editor

Cardurion Pharmaceuticals Inc., a clinical-stage biotechnology company developing next-generation therapeutics for the treatment of cardiovascular diseases, has raised a $260 million Series B financing led by Ascenta Capital, with participation by new investors NEA, GV, Fidelity Management & Research Company, Millennium Management, Farallon Capital Management, Invus, Blue Owl Healthcare Opportunities, Delos Capital and Digitalis Ventures, as well as existing investors Bain Capital Life Scien...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters